Drugs News and Research

RSS

Researchers discover why women with BRCA gene develop breast and ovarian cancer

Researchers announced today in the journal Lancet Oncology that they are well on the way to discovering why women with the faulty genes BRCA 1 and BRCA 2, one of which was inherited by the actress Angelina Jolie, develop breast and ovarian cancer rather than other cancers.

17 Oct 2013

Research findings point the way to new class of antibiotics for skin and heart infections

Researchers at NYU Langone Medical Center have discovered a new mechanism by which the deadly Staphylococcus aureus bacteria attack and kill off immune cells. Their findings, published today in the journal Cell Host & Microbe, explain a critical survival tactic of a pathogen that causes more skin and heart infections than any other microbe, and kills more than 100,000 Americans every year.

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

Light pulses stimulate designer peptides to trigger death pathway in cancerous cells

Researchers at Cardiff University have created a peptide (a small piece of protein), linked to a light-responsive dye, capable of switching 'on' death pathways in cancer cells. The peptide remains inactive until exposed to external light pulses which convert it into a cell death signal.

17 Oct 2013

Certain blood pressure medications may reduce risk of dementia due to Alzheimer's disease

A Johns Hopkins-led analysis of data previously gathered on more than 3,000 elderly Americans strongly suggests that taking certain blood pressure medications to control blood pressure may reduce the risk of dementia due to Alzheimer's disease.

17 Oct 2013

Imaxio Sells Genomics Division To Hybrigenics

...

16 Oct 2013

Jain Foundation Steps Up Efforts To Find Cure For Muscular Dystrophy

...

16 Oct 2013

Pieris Inks Co-Development Alliance With Zydus For Protein Drugs

...

16 Oct 2013

Astrazeneca To Use Wyss Institute’s Organs-On-Chips

AstraZeneca has taken a small step in reducing the need for traditional animal testing by signing on to evaluate Organs-on-Chips from the Wyss Institute for Biologically Inspired Engineering at Harvard.

16 Oct 2013

Deloitte announces upcoming release of PopulationMiner to improve access to patient care

Deloitte today is announcing the upcoming release of PopulationMiner, a real-world, data-analytics solution for gleaning insights and relationships among drugs and diseases across broad patient populations over time and spanning multiple therapeutic and clinical areas.

16 Oct 2013

SAGE Therapeutics obtains $20M Series B financing from two investors

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat central nervous system (CNS) diseases, today announced a $20 million Series B financing from investors ARCH Venture Partners and Third Rock Ventures, bringing the total raised to $57.8 million since launch in 2011.

16 Oct 2013

First Edition: October 16, 2013

Today's headlines including stories detailing how certain health law provisions are factoring in to the continuing congressional budget stalemate.

16 Oct 2013

CU researchers explore why maximum heart rate decreases with age

Researchers at the University of Colorado have new insight into the age-old question of why maximum heart rate decreases with age. This decrease in maxHR not only limits the performance of aging athletes but it is also a leading cause for nursing home admittance for otherwise-healthy elderly individuals who no longer have the physical capacity required for independent living.

16 Oct 2013

Evidence less consistent for high blood sugar, insulin treatment and oral agents

Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University was senior author of a consensus statement from the American Association of Clinical Endocrinologists on diabetes and cancer, which was just published in Endocrinology Practice.

16 Oct 2013

Locomotion of C. elegans worm to make big difference in biomedical research

One might wonder why researchers would even care about the nuances of the one-millimeter long nematode worm, let alone take the time to study them. But the answer is simple: they can provide powerful insights into human health and disease.

16 Oct 2013

Genetics professor turns accidental discovery into a way to study TBI

Faced with news of suicides and brain damage in former professional football players, geneticist Barry Ganetzky bemoaned the lack of model systems for studying the insidious and often delayed consequences linked to head injuries.

16 Oct 2013

Findings shed light on the role of environmental event in development of neural circuits in newborns

Neurons that process sensory information such as touch and vision are arranged in precise, well-characterized maps that are crucial for translating perception into understanding. A study published by Cell Press on October 14 in the journal Developmental Cell reveals that the actual act of birth in mice causes a reduction in a brain chemical called serotonin in the newborn mice, triggering sensory maps to form.

16 Oct 2013

Mindfulness-based intervention leads to drop in blood pressure

Blood pressure is effectively lowered by mindfulness-based stress reduction for patients with borderline high blood pressure or "prehypertension." This finding is reported in the October issue of Psychosomatic Medicine: Journal of Biobehavioral Medicine, the official journal of the American Psychosomatic Society.

16 Oct 2013

Pieris, Zydus Cadila partner to develop and commercialize Anticalin-based protein therapeutics

Zydus Cadila, an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products, and Pieris AG, a next generation therapeutic protein R&D company, have entered into an alliance for development and commercialization of multiple novel Anticalin-based protein therapeutics, both companies announced today.

16 Oct 2013

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint.

16 Oct 2013

Drugs News and Research

Researchers discover why women with BRCA gene develop breast and ovarian cancer

Research findings point the way to new class of antibiotics for skin and heart infections

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Light pulses stimulate designer peptides to trigger death pathway in cancerous cells

Certain blood pressure medications may reduce risk of dementia due to Alzheimer's disease

Imaxio Sells Genomics Division To Hybrigenics

Jain Foundation Steps Up Efforts To Find Cure For Muscular Dystrophy

Pieris Inks Co-Development Alliance With Zydus For Protein Drugs

Astrazeneca To Use Wyss Institute’s Organs-On-Chips

Deloitte announces upcoming release of PopulationMiner to improve access to patient care

SAGE Therapeutics obtains $20M Series B financing from two investors

First Edition: October 16, 2013

CU researchers explore why maximum heart rate decreases with age

Evidence less consistent for high blood sugar, insulin treatment and oral agents

Locomotion of C. elegans worm to make big difference in biomedical research

Genetics professor turns accidental discovery into a way to study TBI

Findings shed light on the role of environmental event in development of neural circuits in newborns

Mindfulness-based intervention leads to drop in blood pressure

Pieris, Zydus Cadila partner to develop and commercialize Anticalin-based protein therapeutics

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News